IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-22834-5.html
   My bibliography  Save this article

Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice

Author

Listed:
  • Eva Conde

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
    Sorbonne University, ED394
    Neovacs SA)

  • Romain Bertrand

    (Neovacs SA)

  • Bianca Balbino

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
    Sorbonne University, ED394)

  • Jonathan Bonnefoy

    (Neovacs SA)

  • Julien Stackowicz

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
    Sorbonne University, ED394)

  • Noémie Caillot

    (Neovacs SA)

  • Fabien Colaone

    (Neovacs SA)

  • Samir Hamdi

    (Neovacs SA)

  • Raïssa Houmadi

    (University Toulouse III)

  • Alexia Loste

    (University Toulouse III)

  • Jasper B. J. Kamphuis

    (University Toulouse III)

  • François Huetz

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM)

  • Laurent Guilleminault

    (University Toulouse III
    Toulouse University Hospital, Faculty of Medicine)

  • Nicolas Gaudenzio

    (University Toulouse III)

  • Aurélie Mougel

    (University Toulouse III)

  • David Hardy

    (Institut Pasteur, Experimental Neuropathology Unit)

  • John N. Snouwaert

    (University of North Carolina at Chapel Hill)

  • Beverly H. Koller

    (University of North Carolina at Chapel Hill)

  • Vincent Serra

    (Neovacs SA)

  • Pierre Bruhns

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM)

  • Géraldine Grouard-Vogel

    (Neovacs SA)

  • Laurent L. Reber

    (Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM
    University Toulouse III)

Abstract

Allergic asthma is characterized by elevated levels of IgE antibodies, type 2 cytokines such as interleukin-4 (IL-4) and IL-13, airway hyperresponsiveness (AHR), mucus hypersecretion and eosinophilia. Approved therapeutic monoclonal antibodies targeting IgE or IL-4/IL-13 reduce asthma symptoms but require costly lifelong administrations. Here, we develop conjugate vaccines against mouse IL-4 and IL-13, and demonstrate their prophylactic and therapeutic efficacy in reducing IgE levels, AHR, eosinophilia and mucus production in mouse models of asthma analyzed up to 15 weeks after initial vaccination. More importantly, we also test similar vaccines specific for human IL-4/IL-13 in mice expressing human IL-4/IL-13 and the related receptor, IL-4Rα, to find efficient neutralization of both cytokines and reduced IgE levels for at least 11 weeks post-vaccination. Our results imply that dual IL-4/IL-13 vaccination may represent a cost-effective, long-term therapeutic strategy for the treatment of allergic asthma as demonstrated in mouse models, although additional studies are warranted to assess its safety and feasibility.

Suggested Citation

  • Eva Conde & Romain Bertrand & Bianca Balbino & Jonathan Bonnefoy & Julien Stackowicz & Noémie Caillot & Fabien Colaone & Samir Hamdi & Raïssa Houmadi & Alexia Loste & Jasper B. J. Kamphuis & François , 2021. "Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22834-5
    DOI: 10.1038/s41467-021-22834-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-22834-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-22834-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22834-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.